Display Settings:

Format

Send to:

Choose Destination
    Neurology. 1992 Jan;42(1 Suppl 1):51-6; discussion 57-60.

    Long-acting carbidopa-levodopa in the management of moderate and advanced Parkinson's disease.

    Source

    Parkinson's Disease Research Center, St. Mary of the Plains Hospital, Lubbock, Texas 79410.

    Abstract

    Parkinson's disease patients treated chronically with levodopa often develop fluctuations in motor response. Motor fluctuations can be attributed in part to oscillating plasma levodopa concentrations. A controlled-release formulation containing 200 mg of levodopa and 50 mg of carbidopa provides superior plasma levodopa profiles compared with the standard preparation. A multicenter, double-blind trial involving 202 patients with fluctuating motor response found controlled-release carbidopa-levodopa to be safe and tolerable, with improved efficacy compared with the standard formulation. Long-term exposure to the controlled-release formulation, at least for a period of 3 years, does not appear to be associated with any increase in the incidence of adverse side effects.

    PMID:
    1549202
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk